or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    RVMD B -1.85 5.67
    SRPT C 6.09 5.35
    MRNA A 0.89 4.95
    MRK A 0.09 4.69
    REGN C -0.09 4.25
    EXEL A 1.80 3.98
    INCY F 0.17 3.79
    BNTX F -0.45 3.36
    GILD F 0.07 3.30
    IOVA D -1.26 3.11
    SWTX C -1.41 2.76
    BGNE D 3.69 2.71
    ACLX D -2.98 2.57
    GERN B 2.29 2.28
    BEAM F -3.11 2.23
    TWST C -2.38 2.10
    DVAX F -2.89 1.95
    DNA F -2.84 1.63
    LGND B 1.59 1.60
    BPMC B -0.03 1.27
    MGNX D -3.27 1.26
    BCRX F -3.88 1.20
    FDMT D -2.26 1.19
    ABCL F -1.76 1.04
    CRSP F -1.35 1.03
    RCUS F -0.45 0.96
    VIR F -1.11 0.94
    DCPH D -0.34 0.92
    NRIX B -2.69 0.86
    ARCT F -3.40 0.86
    IBRX B -12.20 0.86
    EDIT F -2.01 0.60
    NVAX F -0.95 0.58
    OABI F -1.72 0.58
    VALN C 0.09 0.55
    NTLA F -1.67 0.45
    CRBU F -3.27 0.38
    CVAC F -3.46 0.30
    XNCR F 3.54 0.27
    QURE F -4.00 0.27

    Represented by ETF Holdings

    Keywords: Biotechnology Biopharmaceutical Medicine Cancer Life Sciences Biology Immune System Infectious Diseases Clinical Medicine Antibodies Clinical Development Coronavirus Immunology Monoclonal Antibodies Solid Tumors Vaccines Cancer Treatment Disease Genetics Influenza
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research

    Recent News for iShares Genomics Immunology and Healthcare ETF & its Holdings

    Date Stock Title
    Apr 25 GILD US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
    Apr 25 MRK US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
    Apr 25 IBRX Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
    Apr 24 MRK Alphabet, Microsoft, Southwest earnings: What to watch
    Apr 24 DVAX Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
    Apr 24 IOVA Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
    Apr 24 BGNE Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
    Apr 24 RCUS Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
    Apr 24 REGN Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
    Apr 24 CVAC CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
    Apr 24 GILD Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus
    Apr 24 BGNE Evaluating BeiGene: Insights From 6 Financial Analysts
    Apr 24 SWTX SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 24 CRSP Crispr Therapeutics: Now Is The Time To Buy
    Apr 24 CVAC CureVac N.V. 2023 Q4 - Results - Earnings Call Presentation
    Apr 24 VIR What Makes Vir Biotechnology (VIR) a New Buy Stock
    Apr 24 MRK 4 Large Drug Stocks to Hold on to Amid Industry Challenges
    Apr 24 REGN Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
    Apr 24 MRK Merck Q1 Earnings Preview: Strong quarter expectations on the back of core products' growth
    Apr 24 INCY Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
    The investment seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma Index. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
    Exchange Traded Fund Immunology Genomics
    Back to the Main IDNA Page...